- Home
- ECO vs ERAS Comparison
ECO vs ERAS Comparison
Compare ECO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | ERAS |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECO | ERAS |
|---|---|---|
| Price | $45.48 | $14.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $42.00 | $7.20 |
| AVG Volume (30 Days) | 529.9K | ★ 3.4M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 7.00% | N/A |
| EPS Growth | N/A | ★ 16.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.91 | $1.01 |
| 52 Week High | $57.29 | $16.14 |
Technical Indicators
Market Signals| Indicator | ECO | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 63.93 |
| Support Level | $36.82 | $1.46 |
| Resistance Level | $57.29 | N/A |
| Average True Range (ATR) | 1.94 | 0.89 |
| MACD | -0.95 | -0.07 |
| Stochastic Oscillator | 0.00 | 59.40 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.